|Chemical and physical data|
|Molar mass||564.07 g·mol−1|
|3D model (JSmol)|
ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.
- ^ Banister SD, Connor M (2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". Handbook of Experimental Pharmacology. 252: 191–226. doi:10.1007/164_2018_144. ISBN 978-3-030-10560-0. PMID 30105473.
- ^ WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc..
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as hazardous to health] (in Swedish). Folkhälsomyndigheten (The Swedish Public Health Agency). Archived from the original on 25 March 2015. Retrieved 8 July 2015.